These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21894048)

  • 1. Use of predictive markers in oncology: are phase 3 trials always required?
    Markman M
    Oncology; 2011; 81(1):1-2. PubMed ID: 21894048
    [No Abstract]   [Full Text] [Related]  

  • 2. K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
    Wei F; Liu Y; Bellail AC; Olson JJ; Sun SY; Lu G; Ding L; Yuan C; Wang G; Hao C
    Cancer Lett; 2012 Sep; 322(1):58-69. PubMed ID: 22342683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of K-ras mutation analysis in EUS-FNA samples obtained from pancreatic solid mass.
    Matsubayashi H
    J Clin Gastroenterol; 2015 Feb; 49(2):173. PubMed ID: 25076230
    [No Abstract]   [Full Text] [Related]  

  • 4. The KRAS-PDEδ interaction is a therapeutic target.
    Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer in 2017: Rebooting pancreatic cancer knowledge and treatment options.
    Semaan A; Maitra A
    Nat Rev Gastroenterol Hepatol; 2018 Feb; 15(2):76-78. PubMed ID: 29317774
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic adenocarcinoma.
    Ryan DP; Hong TS; Bardeesy N
    N Engl J Med; 2014 Sep; 371(11):1039-49. PubMed ID: 25207767
    [No Abstract]   [Full Text] [Related]  

  • 8. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer.
    Bournet B; Selves J; Grand D; Danjoux M; Hanoun N; Cordelier P; Buscail L
    J Clin Gastroenterol; 2015 Jan; 49(1):50-6. PubMed ID: 24798941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution and dynamics of pancreatic cancer progression.
    Yachida S; Iacobuzio-Donahue CA
    Oncogene; 2013 Nov; 32(45):5253-60. PubMed ID: 23416985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational research in pancreatic cancer: KRAS and beyond.
    Boeck S; Ormanns S; Haas M; Bächmann S; Laubender RP; Siveke JT; Jung A; Kirchner T; Heinemann V
    Pancreas; 2014 Jan; 43(1):150-2. PubMed ID: 24326376
    [No Abstract]   [Full Text] [Related]  

  • 11. KRAS above and beyond - EGFR in pancreatic cancer.
    Siveke JT; Crawford HC
    Oncotarget; 2012 Nov; 3(11):1262-3. PubMed ID: 23174662
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimizing methods for the diagnosis of pancreatic cancer.
    Brugge WR
    J Clin Gastroenterol; 2007; 41(10):869-70. PubMed ID: 18090153
    [No Abstract]   [Full Text] [Related]  

  • 13. Pancreatic ductal adenocarcinoma in hereditary diffuse gastric cancer. A case report.
    Ottenhof NA; de Wilde RF; Morsink FH; de Leng WW; Ausems MG; Morreau H; van Hillegersberg R; Offerhaus GJ; Milne AN
    Hum Pathol; 2012 Mar; 43(3):457-61. PubMed ID: 21992816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
    Strimpakos AS; Saif MW
    JOP; 2013 Jul; 14(4):354-8. PubMed ID: 23846926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
    Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
    Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraductal tubular carcinoma of the pancreas: case report with molecular analysis.
    Furukawa T; Hatori T; Fukuda A; Fujita I; Yamamoto M
    Pancreas; 2009 Mar; 38(2):235-7. PubMed ID: 19238030
    [No Abstract]   [Full Text] [Related]  

  • 17. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.
    Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y
    Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies.
    Fuccio L; Hassan C; Laterza L; Correale L; Pagano N; Bocus P; Fabbri C; Maimone A; Cennamo V; Repici A; Costamagna G; Bazzoli F; Larghi A
    Gastrointest Endosc; 2013 Oct; 78(4):596-608. PubMed ID: 23660563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
    Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
    Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.